TY - JOUR
TI - Resource utilisation and clinical data before and after switching
between short-acting human insulin and rapid-acting insulin analogues in
patients with type 2 diabetes: The SWING study
AU - Reaney, Matthew
AU - Cypryk, Katarzyna
AU - Tentolouris, Nicholas and
AU - Jecht, Michael
AU - Cleall, Simon
AU - Petzinger, Ute
AU - Koivisto, Veikko
JO - Diabetes Research and Clinical Practice
PY - 2012
VL - 97
TODO - 2
SP - 231-241
PB - Elsevier Ireland Ltd
SN - 0168-8227
TODO - 10.1016/j.diabres.2012.02.024
TODO - Diabetes mellitus; Type 2; Insulin; Analogue; Lispro; Aspart
TODO - Aim: SWING was a prospective, observational study conducted in nine
European countries primarily to assess direct treatment costs when
switching from short-acting human insulins to rapid-acting insulin
analogues (H-A) or vice versa (A-H) in patients with type 2 diabetes.
Methods: Data were collected at a baseline visit (time of switch) and at
approximately 3, 6 and 12 months post-switch.
Results: In total, 2389 patients switched from H-A (n = 2203) or A-H (n
= 186); another 603 were enrolled but ineligible. Mean (SD) direct
diabetes-related costs (pro-rated to account for variable visit
schedules) were (sic)548.7 (865.8) 6 months prior to switch, (sic)625.6
(1474.9) at 0-6 months and (sic)568.6 (590.7) 6-12 months following
switch for H-A, and (sic)544.5 (421.0), (sic)481.0 (301.5) and
(sic)461.6 (335.0) for A-H, respectively. Mean (SD) HbA(1c) decreased
over 12 months by 1.08 (1.53)% units H-A and 1.17 (1.45)% units A-H. A
small decline in hypoglycaemia occurred over time, but there were no
clinically meaningful changes in mean PROs.
Conclusions: There were small changes in mean direct diabetes-related
costs (following adjustment for time interval) in patients switching in
either direction. Improvements in mean HbA(1c) and incidence of
hypoglycaemia cannot necessarily be attributed to therapeutic switch.
(C) 2012 Elsevier Ireland Ltd. All rights reserved.
ER -